•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Processa Pharmaceuticals, Inc. (PCSA) Presents at UBS Global Biopharma Conference 2026 Transcript
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals Announces Key Leadership Appointments
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks Transcript
Processa buys Vidya Therapeutics, raises $200 million for drug trials
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)
Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate